Matthew Jones Net Worth

Matthew Jones biography

Matthew S. Jones serves as Managing Director - Business Development and Licensing of the Company. Matthew S. Jones joined Dyadic as a consultant in May 2016 and serves as our consultant commercial officer / Business Development and Licensing to lead Dyadic’s strategic partnerships, licensing and commercial opportunities within and across the biopharmaceutical industry. A veteran of the life sciences industry with two decades of commercial deal making and leadership experience, Mr. Jones has developed and implemented strategies which have delivered revenue growth, organically and through acquisitions, for a diverse range of life science businesses both in Europe and the US. Prior to joining Dyadic, Mr. Jones served as Chief Commercial Officer for Concept Life Sciences from its formation until 2016. Prior to that, Mr. Jones advised several private equity buy and builds and was also Vice President of Global Sales & Business Development at Lonza Biologics, where he implemented new income-generating revenue streams and captured enterprise synergies in manufacturing, research and client/vendor relationships. From 2009 to 2012, Mr. Jones served as Executive Vice President of Business Development & Marketing at Ricerca Biosciences LLC, responsible for strategic partnerships, royalty and asset license optimization and marketing effectiveness and where Mr. Jones supported the Bain Ventures trade sale of the business toward WiL research. From 2003 to 2009, Mr. Jones was Senior Vice President of Business Development at MDS Pharma Services Inc., where he was responsible for global biopharmaceutical and clinical commercial growth strategies. Earlier in his career, Mr. Jones also held senior level leadership roles within the biopharmaceutical industry with Alkermes, Inc. and GlaxoSmithKline plc. Mr. Jones is a graduate of Warwick University and London Business School.

What is the salary of Matthew Jones?

As the Managing Director - Business Development and Licensing of Dyadic International, the total compensation of Matthew Jones at Dyadic International is $421,163. There are 2 executives at Dyadic International getting paid more, with Mark Emalfarb having the highest compensation of $1,074,050.

How old is Matthew Jones?

Matthew Jones is 42, he's been the Managing Director - Business Development and Licensing of Dyadic International since 2017. There are 11 older and no younger executives at Dyadic International. The oldest executive at Dyadic International, Inc. is Jack Kaye, 76, who is the Independent Director.

What's Matthew Jones's mailing address?

Matthew's mailing address filed with the SEC is 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER, FL, 33477-5094.

Insiders trading at Dyadic International

Over the last 5 years, insiders at Dyadic International have traded over $118,246,658,250 worth of Dyadic International stock and bought 27,000 units worth $100,230 . The most active insiders traders include Mark A Emalfarb, Ronen Tchelet und Seth Herbst. On average, Dyadic International executives and independent directors trade stock every 73 days with the average trade being worth of $54,365. The most recent stock trade was executed by Barry Buckland on 11 June 2024, trading 11,793 units of DYAI stock currently worth $18,751.

What does Dyadic International do?

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.

Dyadic International executives and stock owners

Dyadic International executives and other stock owners filed with the SEC include:

• Mark Emalfarb,
  President, Chief Executive Officer, Director
• Mark A. Emalfarb,
  Founder, CEO, Pres & Director
• Matthew Jones,
  Managing Director - Business Development and Licensing
• Ping Rawson,
  Chief Financial Officer, Chief Accounting Officer
• Matthew S. Jones,
  Managing Director of Bus. Devel. & Licensing
• Ronen Tchelet,
  Vice President of Research and Business Development
• Dr. Ronen Tchelet Ph.D.,
  VP of Research & Bus. Devel.
• Jack Kaye,
  Independent Director
• Arindam Bose,
  Independent Director
• Michael Tarnok,
  Independent Chairman of the Board
• Seth Herbst,
  Independent Director
• Barry Buckland,
  Independent Director
• Ana Gómez Rodriguez,
  Sec. of the Board
• Joseph P. Hazelton,
  Chief Bus. Officer
• Patrick K. Lucy,
  Director
• Trust Under Agreement Dated...,
  10% owner
• Joseph P Hazelton,
  Chief Business Officer